ParaPRO announced that the Food and Drug Administration (FDA) has approved an expanded age range for Natroba (spinosad) Topical Suspension, to include children 6 months of age and older who have pediculosis capitis (head lice).
Widespread use of pyrethrins- or pyrethroid-based products appears to have resulted in selection pressure for a highly-resistant strain of human head lice in North America.
Teledermatology is reliable for initial triage of patients, according to a study published online.
A single 10-minute, at-home treatment with topical ivermectin lotion eliminates head lice infestations in nearly all patients by the next day.
Sanofi Pasteur announced that Sklice (ivermectin) Lotion, 0.5%, is now available for the treatment of head lice in patients 6 months of age and older.
Although live head lice obtained from school-aged children in Paris remain susceptible to the insecticide malathion, approximately 14% have been found to be resistant to permethrin, suggesting a strong basis for future insecticide resistance.
Sanofi announced that the FDA has approved Sklice (ivermectin lotion) 0.5% for the topical treatment of head lice in patients ≥6 months of age.
This patient information fact sheet provides information on the definition, causes, symptoms, detection and treatments for head lice infestation.
Lice and scabies treatment chart, including pediculicides, scabicides, and lice and nit removal aids.
Topaz Pharmaceuticals announced the FDA has accepted for filing the NDA for ivermectin, a topical cream used to treat head lice in children and adults.
